Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
| dc.contributor.author | Voorham, Jaco | |
| dc.contributor.author | Roche, Nicolas | |
| dc.contributor.author | Benhaddi, Hicham | |
| dc.contributor.author | van der Tol, Marianka | |
| dc.contributor.author | Carter, Victoria | |
| dc.contributor.author | van Boven, Job F. M. | |
| dc.contributor.author | Bjermer, Leif | |
| dc.contributor.author | Miravitlles, Marc | |
| dc.contributor.author | Price, David B. | |
| dc.contributor.institution | University of Aberdeen.Institute of Applied Health Sciences | en |
| dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en |
| dc.date.accessioned | 2018-12-12T05:22:05Z | |
| dc.date.available | 2018-12-12T05:22:05Z | |
| dc.date.issued | 2018-10 | |
| dc.description | Acknowledgements: The authors thank Derek Skinner, Francis Appiagyei and Tanith Hjelmbjerg of the Observational and Pragmatic Research Institute for providing assistance with data analysis. The authors also thank Ian Grieve and Bill Watkins of Ashfield Healthcare Communications, part of UDG Healthcare, for providing medical writing support. The authors thank Teva Pharmaceuticals for providing a full review of the article. Funding: This study was supported by Teva Pharmaceuticals and undertaken by OPRI (http://opri.sg). Medical writing support was funded by Teva Pharmaceuticals | en |
| dc.description.status | Peer reviewed | en |
| dc.format.extent | 12 | |
| dc.format.extent | 1663478 | |
| dc.identifier | 141027523 | |
| dc.identifier | 914d48e9-75e5-4bac-8fff-895cabfa76ad | |
| dc.identifier | 30368448 | |
| dc.identifier | 85055659550 | |
| dc.identifier.citation | Voorham, J, Roche, N, Benhaddi, H, van der Tol, M, Carter, V, van Boven, J F M, Bjermer, L, Miravitlles, M & Price, D B 2018, 'Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK', BMJ Open, vol. 8, no. 10, e022051, pp. 1-12. https://doi.org/10.1136/bmjopen-2018-022051 | en |
| dc.identifier.doi | 10.1136/bmjopen-2018-022051 | |
| dc.identifier.iss | 10 | en |
| dc.identifier.issn | 2044-6055 | |
| dc.identifier.uri | http://hdl.handle.net/2164/11604 | |
| dc.identifier.vol | 8 | en |
| dc.language.iso | eng | |
| dc.relation.ispartof | BMJ Open | en |
| dc.subject | R Medicine (General) | en |
| dc.subject.lcc | R1 | en |
| dc.title | Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK | en |
| dc.type | Journal article | en |
